Phase I study of gemcitabine using a once every 2 weeks schedule.

Gemcitabine (2',2'-difluorodeoxycytidine) is a novel nucleoside analogue. As part of a series of studies to determine the maximum tolerated dose (MTD) of gemcitabine and the most appropriate schedule, a two-centre phase I study of gemcitabine was undertaken in patients with advanced refrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermorken, J. B., Guastalla, J. P., Hatty, S. R., Seitz, D. E., Tanis, B., McDaniels, C., Clavel, M. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228173/
https://www.ncbi.nlm.nih.gov/pubmed/9400947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228173/
https://www.ncbi.nlm.nih.gov/pubmed/9400947

Ejemplares similares